Back

Sex differences in the use of rhythm control strategies in patients with atrial fibrillation in FinACAF study

29 August 2022 (15:15 - 15:55)
Organised by:
Congress Presentation Part of: Atrial fibrillation: rate or rhythm control Treatment ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Ms Ksenia Kalatsova

University of Helsinki, Helsinki (Finland)

5 More presentations in this session

Presentation thumbnail
Association between early rhythm control and the risk of dementia in patients with atrial fibrillation and prior history of stroke: a nationwide population-based study
Doctor S. Lee (Seoul, KR)
Abstract Slides
Presentation thumbnail
Effect of dronedarone versus placebo on atrial fibrillation progression: a post-hoc analysis from ATHENA trial
Professor M. Blomstrom-Lundqvist (Orebro, SE)
Abstract Slides
Presentation thumbnail
Dronedarone versus sotalol in patients with atrial fibrillation: a systematic literature review and network meta-analysis
Professor J. Camm (London, GB)
Abstract Slides
Presentation thumbnail
Holistic approach of ablation versus antiarrhythmic drugs for efficacy, safety, and quality of life improvement in rhythm control of atrial fibrillation: a meta-analysis of randomized trials
Mr G. Prana Jagannatha (Denpasar, ID)
Abstract Slides
Presentation thumbnail
Prevalence of modifiable risk factors and related poor cardiovascular outcomes following atrial fibrillation ablation
Doctor K. Stout (Omaha, US)
Abstract Slides

Access the full session

Session thumbnail
Atrial fibrillation: rate or rhythm control

The Event

Event poster

ESC Congress 2022

29 August 2022 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Sex differences in procedural outcomes after pulsed field ablation to treat atrial fibrillation. Sub-analysis of the global FARADISE registry
thumbnail
Congress Presentation
Impact of sex on atrial structure, function, and atrial fibrillation recurrence following pulmonary vein isolation
thumbnail
Congress Presentation
Sex differences in long-term clinical effectiveness after pulsed field ablation to treat atrial fibrillation. Sub-analysis of the global FARADISE registry

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources